Similar Articles

Home | Newsletter | My Articles | My Account | Help

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 4, 2012 Sean Williams	2012 Preview: K-V Pharmaceuticals Conserving cash will be a primary objective for K-V in 2012.
The Motley Fool May 26, 2011 Brian Orelli	Congress Sets Bad Precedent With AVANIR What happened to free markets?
The Motley Fool April 20, 2011 Sean Williams	KV Pharmaceuticals: From Sell to Belle in a Month Don't write off this company just yet.
The Motley Fool November 23, 2011 Brian Orelli	I Was Wrong About Dendreon But maybe not in the long term.
The Motley Fool March 28, 2011 Brian Orelli	Investors Jump for Yervoy! The Food and Drug Administration approval of Bristol-Myers Squibb's Yervoy came with some surprising labeling news.
Pharmaceutical Executive May 1, 2011 Jill Wechsler	Outrage Over Drug Prices Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies
The Motley Fool August 29, 2011 Brian Orelli	We Can Make More! Too Bad Few Want It Dendreon is no longer constrained by its supply.